John P. Butler

John P. Butler

President and Chief Executive OfficeratAkebia Therapeutics· In proxies 2021–2025

Pay in FY2025+33% from the year before · Akebia Therapeutics stock -15.3% the same year

John P. Butler was paid $5.7M in FY2025 (Dec), up 33%. Akebia Therapeutics stock fell 15.3% that year.

Pay$100 in the stock at the end of FY20 → $58
Pay is from the Summary Compensation Table of each Akebia Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Akebia TherapeuticsPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrStock in role -74%
  2. American Kidney FundPublic company
    • Director? – PresentNo stock prices for these years
  3. WaveBreak Therapeutics, IncPublic company
    • Director? – PresentNo stock prices for these years
  4. Relypsa, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Zynerba Pharmaceuticals, Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Kidney Care PartnersPublic company · 4 yr
    • Director2020 – 2024 · 4 yrNo stock prices for these years
  7. Keryx Biopharmaceuticals, Inc.Public company · 1 yr
    • Director2016 – 2017 · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?